SUPAC level 3 changes for MR formulations [Regulatives / Guidelines]
❝ 1. IR product if we change the manufacturing site, do we need to perform BE study as suggested in SUPAC guidance for IR? or it would be okay to justify based on in vitro data?
Did you read the SUPAC guidance for IR?
❝ 2. For MR product SUPAC MR guidance is not clear for any requirement of conducting BE study. where as we do perform Fasting for such changes in manufacturing site change. are we doing correct?
I dont follow. Are you asking if the study should be a fasted study?